Search results: (10000)
News Effect of Etanercept on Structural Changes in the Sacroiliac Joint in Patients with Early Axial Spondyloarthritis
Currently, there is limited evidence regarding the effect of tumor necrosis factor inhibitors on structural lesions in patients with early forms of axial spondyloarthritis (AxSpA). The aim of the study presented below, published in January 2021, was to evaluate structural changes in the sacroiliac joint (SIJ) on magnetic resonance imaging (MRI) after 2 years of treatment with etanercept within the clinical study EMBARK in patients with early AxSpA compared to a control cohort not treated with biologics (DESIR) and to assess the relationship between MRI changes and disease activity according to ASDAS.
News Monitoring of Joint Health is an Important Part of Hemophilia Care
Joint health has become a key aspect of the quality of life for people with hemophilia. The possibilities of monitoring early joint damage in hemophiliacs were evaluated in a recently published British study.
News Recommendations for Nutrition of Patients at Risk of or with Pressure Ulcers
Nutrition plays a crucial role in the prevention and treatment of pressure ulcers. In 2019, international recommendations for the nutrition of individuals at risk of or already with pressure ulcers were developed. Based on published evidence, they were prepared by expert groups PUAP/NPIAP/PPPIA (Pressure Ulcer Advisory Panel, National Pressure Injury Advisory Panel, Pan Pacific Pressure Injury Alliance Prevention) as a clinical practice guide for doctors and nurses.
News The Position of Lurasidone in Schizophrenia Therapy − Current Conclusions and Consensus of the Expert Panel
Lurasidone is an antipsychotic belonging to the group of serotonin and dopamine antagonists (SDA) indicated for the treatment of schizophrenia in adults and adolescents aged 13 years and older. The efficacy of lurasidone has been confirmed by a number of clinical studies, compared to placebo and using active control with known antipsychotics (e.g., olanzapine or quetiapine). The aim of the recently published study was to define current possibilities of using lurasidone in the treatment of schizophrenia and to identify patient groups that would benefit the most from this therapy.
News Perioperative substitution therapy in patients with vWD must be tailored
Even in cases of von Willebrand disease (vWD), available data supports the need for individualized approaches in ensuring surgical procedures to prevent FVIII accumulation and high factor consumption.
News Another Piece of the Puzzle for More Accurate Dosing of Clotting Factors in von Willebrand Disease
A study published last year in the Journal of Thrombosis and Haemostasis presents the results of Dutch hematologists who created a pharmacokinetic model to refine the dosing of clotting factors during surgery in patients with von Willebrand disease (vWD).
News Is it safe to start dabigatran in the first days after ischemic stroke?
For patients after cardioembolic ischemic stroke (iCMP), starting anticoagulant therapy is crucial, but it is not strictly defined how many days after iCMP it is ideal to begin. The article provides a summary of a recent observational study that investigated the appropriate timing of starting dabigatran in patients with non-valvular atrial fibrillation (NVAF) after their first iCMP who were treated with intravenous thrombolysis or endovascular thrombectomy.
News New Strategies in the Treatment of Schizophrenia
Schizophrenia was primarily associated with dopamine dysfunction. Previous and current treatments have mainly targeted the mesolimbic dopamine pathway in the CNS and D2 receptors. However, the cited review article primarily addresses newer treatment targets and strategies beyond the dopamine hypothesis.
News Alemtuzumab – Does Age Matter? Or Not?
The authors of a study published this year focused on the safety and efficacy of alemtuzumab in patients with relapsing-remitting multiple sclerosis (RRMS). How did it perform over the observed period in patients of different age categories?
News Does Teriflunomide Bloom at Every Age?
What impact does age have on the effectiveness of multiple sclerosis (MS) therapy in real-world clinical practice? How do the outcomes differ for patients treated with teriflunomide considering their age and previous therapy? The authors of a study published this year in the journal Therapeutic Advances in Neurological Disorders focused on the efficacy and safety of teriflunomide in real-world clinical practice with regard to age and prior treatment.
News Final Analysis of the STASEY Study: How Did Emicizumab Fare in the Prophylaxis of Hemophilia A Patients with FVIII Inhibitors?
The July virtual congress of the International Society on Thrombosis and Haemostasis (ISTH) 2021 offered a variety of interesting topics. Among the poster presentations, data from the multicenter, single-arm, open-label phase III STASEY clinical trial, which evaluated the safety and tolerability of emicizumab prophylaxis in patients with hemophilia A and an FVIII inhibitor, were included. The results were presented on behalf of an international team of authors by Víctor Jiménez-Yuste from the University Hospital La Paz in Madrid.
News Optimization of Romiplostim Administration in ITP Treatment
In their newly published review article, authors from several American institutions summarize findings on the role of romiplostim in the treatment of immune thrombocytopenia (ITP) and its efficacy and safety. Among other things, they provide the latest data on its early administration as early as 3 months after the onset of the disease, discuss the possibility of achieving remission without the need for further treatment, and also address practical aspects of therapy.
News Nasal Smear as a Modern and Gentle Diagnostic Method for Allergic Rhinitis
Up to 130 million Europeans suffer from allergic rhinitis. Until now, standard diagnostic methods have been skin prick tests and laboratory blood tests. Both methods, however, present significant discomfort for many patients, and skin prick tests can also yield false-positive results. That's why researchers are focusing on new diagnostic possibilities for allergic rhinitis.
News Treatment of Metastatic Colorectal Cancer During the COVID-19 Pandemic
In the conditions of the coronavirus pandemic, it is difficult to maintain good accessibility to ongoing comprehensive oncological care, and thus the quality of life of patients. An international team of researchers focused their survey among oncologists on how the pandemic affects the goals of 3rd line therapy in patients with metastatic colorectal cancer (mCRC) in real clinical practice. The survey results were presented at this year's virtual congress on the treatment of gastrointestinal tumors of the European Society for Clinical Oncology (ESMO).
News Biosimilar MB02 as an Alternative to Bevacizumab in Lung Cancer Treatment
The STELLA clinical trial aimed to evaluate the efficacy, safety, and immunogenicity of MB02, a biosimilar to bevacizumab, in patients with advanced non-small cell lung cancer.